Is RVMD or RXRX more undervalued in 2026?

CirclFi compares Revolution Medicines, Inc. (RVMD) and Recursion Pharmaceuticals, Inc. (RXRX) using 13 institutional-grade valuation models. RVMD has a Quality of Company score of 5.1/10 while RXRX scores 6.5/10.

Which is a better buy — RVMD or RXRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RVMD and RXRX valuations compare?

RVMD at $154.63 and RXRX at $3.44 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RVMD vs RXRX Valuation Comparison 2026 — Intrinsic Value Analysis

RVMD

Biotechnology

Revolution Medicines, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$154.63

Last close

Models

12/13

Active

RXRX

Biotechnology

Recursion Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$3.44

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	RVMD Fair Value	RVMD Upside	RXRX Fair Value	RXRX Upside
Bayesian DCF	Intrinsic	$53.27	-65.5%	$1.52	-55.8%
Earnings Power Value	Intrinsic	$64.04	-52.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$7.06	-95.4%	$1.99	-42.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RVMD vs RXRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RVMD vs RXRX — Which Stock Is More Undervalued?

RXRX scores higher with a 6.5/10 quality rating vs RVMD's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Revolution Medicines, Inc. (RVMD) and Recursion Pharmaceuticals, Inc. (RXRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RVMD currently trades at $154.63 with a QOC of 5.1/10, while RXRX trades at $3.44 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).